- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06323174
Исследование, призванное выяснить, насколько CagriSema снижает уровень сахара в крови и массу тела по сравнению с плацебо у людей с диабетом 2 типа, получающих диету и физические упражнения (REIMAGINE 1)
Эффективность и безопасность совместного применения кагрилинтида и семаглутида (CagriSema) п/к. в дозах 2,4 мг/2,4 мг и 1,0 мг/1,0 мг один раз в неделю по сравнению с плацебо у участников с диабетом 2 типа, недостаточно контролируемым диетой и физическими упражнениями
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
-
Budapest, Венгрия, 1032
- Szent Margit Rendelőintézet Nonprofit Kft.
-
Budapest, Венгрия, 1102
- PVN Kutató Kft.
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Венгрия, 4025
- Belinus Bt.
-
-
Szabolcs-Szatmar Varmegye
-
Nyíregyháza, Szabolcs-Szatmar Varmegye, Венгрия, 4405
- Borbánya Praxis E.Ü. Kft.
-
-
-
-
-
Bergamo, Италия, 24127
- Azienda Ospedaliera Papa Giovanni XXIII
-
Catanzaro, Италия, 88100
- Policlinico Mater Domini Università di Catanzaro
-
Milan, Италия, 20132
- IRCCS Ospedale San Raffaele Milano
-
Roma, Италия, 00161
- Azienda Ospealiero Universitaria Policlinico Umberto I
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай, 100853
- Chinese People's Liberation Army General Hospital-Endocrinology
-
-
Jiangsu
-
Nanjing, Jiangsu, Китай, 210011
- The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
-
Zhenjiang, Jiangsu, Китай, 212001
- The Affiliated Hospital of Jiangsu University-Endocrinology
-
-
Shandong
-
Ji'Nan, Shandong, Китай, 250000
- Jinan Central Hospital
-
Jinan, Shandong, Китай, 250000
- Jinan Central Hospital
-
-
-
-
-
Bialystok, Польша, 15-351
- Osteo-Medic s.c. A. Racewicz, J. Supronik
-
Bialystok, Польша, 15-797
- Renew Clinic Sp. z o.o.
-
Lodz, Польша, 90-338
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
-
Warsaw, Польша, 02-507
- Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
-
Warsaw, Польша, 00-710
- NBR Polska Tomasz Klodawski
-
Zamość, Польша, 22-400
- Velocity Nova Sp. z o.o.
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Польша, 35-055
- Centrum Medyczne Medyk Sp. z o.o.
-
-
-
-
-
Al Ahsa, Саудовская Аравия, 36428
- King Abdulaziz Hospital-Al Ahsa-National Guard
-
Jeddah, Саудовская Аравия, 21423
- National Guard Hospital - Jeddah
-
Riyadh, Саудовская Аравия, 11525
- King Fahad Medical City
-
Riyadh, Саудовская Аравия, 12372
- King Khaled University Hospital,King Saud Univ. Med. City
-
Riyadh, Саудовская Аравия, 12769
- King Salman Bin Abdulaziz Hospital
-
-
-
-
-
Belgrade, Сербия, 11080
- Clinical Hospital Center Bezanijska Kosa
-
Belgrade, Сербия, 11080
- Clinical Hospital Centre Zemun
-
Belgrade, Сербия, 11000
- CHC Zvezdara, Clinical department for endocrinology
-
Zaječar, Сербия, 19000
- Policlinic for diabetes
-
-
-
-
California
-
Huntington Park, California, Соединенные Штаты, 90255
- Nat Res Inst Huntington Park
-
Northridge, California, Соединенные Штаты, 91325
- Valley Clinical Trials, Inc.
-
Santa Ana, California, Соединенные Штаты, 92701
- Southern California Dermatology
-
-
Florida
-
Hollywood, Florida, Соединенные Штаты, 33024
- Encore Medical Research LLC
-
Orlando, Florida, Соединенные Штаты, 32819
- Headlands Research Orlando
-
Weston, Florida, Соединенные Штаты, 33331
- Encore Medical Research of Weston
-
-
Kansas
-
Newton, Kansas, Соединенные Штаты, 67114
- Alliance for Multispec Res
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02115
- Brigham & Women's Hospital
-
-
Michigan
-
Troy, Michigan, Соединенные Штаты, 48098
- Arcturus HC PLC Troy Med Res
-
-
New York
-
West Seneca, New York, Соединенные Штаты, 14224
- Southgate Medical Group, LLP
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97210
- Summit Research Network Oregon Inc.
-
-
Tennessee
-
Kingsport, Tennessee, Соединенные Штаты, 37660
- Holston Medical Group
-
-
Texas
-
Amarillo, Texas, Соединенные Штаты, 79124
- Amarillo Medical Specialists
-
Austin, Texas, Соединенные Штаты, 78704
- Elligo Clin Res Centre
-
Brownsville, Texas, Соединенные Штаты, 78526
- Headlands Research Brownsville
-
Dallas, Texas, Соединенные Штаты, 75230
- Velocity Clinical Res-Dallas
-
San Antonio, Texas, Соединенные Штаты, 78233
- Northeast Clinical Research of San Antonio
-
Shavano Park, Texas, Соединенные Штаты, 78231
- Consano Clinical Research, LLC
-
Sugar Land, Texas, Соединенные Штаты, 77479
- Sugar Lakes Family Practice PA
-
Weslaco, Texas, Соединенные Штаты, 78596
- Valley Diab. & Endo Comp Ctr
-
-
Virginia
-
Newport News, Virginia, Соединенные Штаты, 23606
- TPMG Clinical Research
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Male or female
- Age 18 years or above at the time of signing the informed consent
- Diagnosed with type 2 diabetes >=30 days before screening
- HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
- Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening
Exclusion Criteria:
- Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
- Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
- Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
- History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Активный компаратор: CagriSema Dose 2
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks. |
Participants will receive once-weekly cagrilintide subcutaneously. Participants will receive once-weekly semaglutide subcutaneously. |
|
Плацебо Компаратор: Placebo Dose 2
Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks. |
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously. |
|
Активный компаратор: Cagrisema Dose 1
Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks. |
Participants will receive once-weekly cagrilintide subcutaneously. Participants will receive once-weekly semaglutide subcutaneously. |
|
Плацебо Компаратор: Placebo Dose 1
Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks. |
Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in glycated haemoglobin (HbA1c)
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as percentage (%)-points. |
From baseline (week 0) to end of treatment (week 40)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Relative change in body weight
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured in %. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=15% body weight reduction
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
Временное ограничение: At end of treatment (week 40)
|
Measured as count of participants. |
At end of treatment (week 40)
|
|
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)
Временное ограничение: At end of treatment (week 40)
|
Measured as count of participants. |
At end of treatment (week 40)
|
|
Change in Fasting Plasma Glucose (FPG)
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured in millimoles per liter (mmol/L). |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=5% body weight reduction
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve >=20% body weight reduction
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as count of participants. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in waist circumference
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured in centimeters (cm). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in systolic blood pressure (SBP)
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured in millimeters of mercury (mmHg). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in diastolic blood pressure (DBP)
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured in mmHg. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Total cholesterol
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Triglycerides
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Free fatty acids
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Ratio to baseline in lipids: Non-HDL cholesterol
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)
Временное ограничение: At end of study (week 52)
|
Measured as count of participants. |
At end of study (week 52)
|
|
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as ratio. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in SF-36v2 score: Physical Component Summary score
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in SF-36v2 score: Mental Component Summary score
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7. |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in leptin
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured in nanograms per milliliter (ng/mL). |
From baseline (week 0) to end of treatment (week 40)
|
|
Change in soluble leptin receptor
Временное ограничение: From baseline (week 0) to end of treatment (week 40)
|
Measured in ng/mL. |
From baseline (week 0) to end of treatment (week 40)
|
|
Number of Treatment Emergent Adverse Events (TEAEs)
Временное ограничение: From baseline (week 0) to end of treatment +7 weeks (week 47)
|
Measured as count of events. |
From baseline (week 0) to end of treatment +7 weeks (week 47)
|
|
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter
Временное ограничение: From baseline (week 0) to end of treatment +7 weeks (week 47)
|
Measured as count of episodes. |
From baseline (week 0) to end of treatment +7 weeks (week 47)
|
|
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Временное ограничение: From baseline (week 0) to end of treatment + 7 weeks (week 47)
|
Measured as count of episodes. |
From baseline (week 0) to end of treatment + 7 weeks (week 47)
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- NN9388-4895
- 2022-502677-42 (Другой идентификатор: European Medical Agency (EMA))
- U1111-1283-0404 (Другой идентификатор: World Health Organization (WHO))
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .